Health Canada Approves AbbVie Treatment for Bipolar Disorder, Schizophrenia
April 27 2022 - 7:53AM
Dow Jones News
By Adriano Marchese
AbbVie Inc. said Wednesday that Health Canada has approved its
treatment for symptoms associated with bipolar disorder and
schizophrenia in the country.
The regulator approved the use of VRAYLAR, also known as
cariprazine, as a monotherapy for the acute management of manic,
mixed and depressive episodes associated with bipolar 1 disorder in
adults, AbbVie said.
The drug would also be used in the treatment of schizophrenia in
adults, the biopharmaceutical company said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 27, 2022 07:38 ET (11:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024
